Extension of NetraMark’s NetraPharma Collaboration with Juvenescence December 10, 2019 NetraMark Corp. and Juvenescence are excited to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.
AgeX Therapeutics Issues Year-End Letter to Shareholders December 09, 2019 At the end of its first year as a public company, Juvenescence partner AgeX issues a letter shareholders reflecting on progress made, as well as current initiatives and future plans.
AgeX Therapeutics and Juvenescence Publish Engineering Strategies for Universal Cells October 30, 2019 AgeX Therapeutics, a biotechnology company, and Juvenescence, a biotech longevity company, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine.
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of Liver Regeneration Technology October 21, 2019 LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision...
AgeX Therapeutics publishes Theoretical Basis of Human Cell-Age Reversal in the Journal of Regenerative Medicine August 28, 2019 AgeX Therapeutics, a Juvenescence biotechnology company focused on therapeutics for human aging and regeneration, announced today, the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
Juvenescence closes $100 Million Series B Round August 19, 2019 Juvenescence, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity.
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments May 28, 2019 Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Juvenescence Capitalizes BYOMass March 27, 2019 Juvenescence is pleased to announce its latest equity investment in BYOMass, a Massachusetts-based company focused on central control of metabolism in the context of aging and age-related diseases.
Juvenescence and the Buck Institute launch BHB Therapeutics February 04, 2019 Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics a joint venture.
Juvenescence closes First $46M Tranche of $100M Series B January 16, 2019 Juvenescence is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million.
Juvenescence, The Buck Institute, and Insilico Medicine establish Napa Therapeutics August 14, 2018 Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine announced today that they have formed Napa Therapeutics, to develop drugs against a novel aging-related target.
Juvenescence Series A, Nets $50 Million June 11, 2018 Juvenescence has successfully raised $50 million in its Series A financing. The Series A financing was oversubscribed with participation from founders, insiders, institutional investors and family offices.